• CD21low plasmablasts are significantly increased in patients after allo-SCT before cGVHD onset.

  • Expanded plasmablast-derived immunoglobulin A antibody clones bind to commensal microbiota.

Abstract

Chronic graft-versus-host disease (cGVHD) is characterized by dysregulation of the adaptive immune system, including an aberrant B-cell homeostasis after allogeneic hematopoietic stem cell transplantation (allo-SCT). It is uncertain, however, whether this B-cell dysregulation is a result of manifest cGVHD or develops as a sign of aberrant B lymphopoiesis after allo-SCT before cGVHD becomes apparent. To gain insight into the development of B-cell dysregulation before the onset of cGVHD, we analyzed B-cell subpopulations by multiparameter flow cytometry on days 90, 180, and 356 after allo-SCT in a prospective study design. After completion of follow-up, patients were assigned retrospectively to 3 groups according to onset of GVHD: (1) no GVHD (n = 17); (2) acute GVHD (aGVHD) without subsequent cGVHD (n = 32); and (3) cGVHD (n = 59). Although CD21lowCD11c+ B cells were increased in all groups, the frequency of CD20CD38hi plasmablasts was significantly elevated already 90 days after allo-SCT in patients who subsequently developed cGVHD, compared to patients without GVHD or with aGVHD only (median of CD19+ cells, 5.9% vs 2.2% vs 2.2%; P = .0016 and .0304, respectively). Detailed molecular analysis of expanded plasmablasts revealed a dominance of the immunoglobulin A isotype, with molecular evidence for recent generation in mucosal sites and markers for intestinal homing. A large fraction of the clonally expanded plasmablasts produced antibodies that bound to subgroups of commensals known to produce short-chain fatty acids. In summary, our data suggest that dysregulated intestinal antibody responses against commensals contribute to the pathophysiology of cGVHD.

1.
Socié
G
,
Stone
JV
,
Wingard
JR
, et al
.
Long-term survival and late deaths after allogeneic bone marrow transplantation. Late effects Working Committee of the International Bone Marrow Transplant registry
.
N Engl J Med
.
1999
;
341
(
1
):
14
-
21
.
2.
Higman
MA
,
Vogelsang
GB
.
Chronic graft versus host disease
.
Br J Haematol
.
2004
;
125
(
4
):
435
-
454
.
3.
Lee
SJ
,
Flowers
MED
.
Recognizing and managing chronic graft-versus-host disease
.
Hematol Am Soc Hematol Educ Progr
.
2008
;
2008
(
1
):
134
-
141
.
4.
Arai
S
,
Arora
M
,
Wang
T
, et al
.
Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research
.
Biol Blood Marrow Transpl
.
2015
;
21
(
2
):
266
-
274
.
5.
Cooke
KR
,
Luznik
L
,
Sarantopoulos
S
, et al
.
The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease
.
Biol Blood Marrow Transpl
.
2017
;
23
(
2
):
211
-
234
.
6.
Zeiser
R
,
Blazar
BR
.
Pathophysiology of chronic graft-versus-host disease and therapeutic targets
.
N Engl J Med
.
2017
;
377
(
26
):
2565
-
2579
.
7.
Wolff
D
,
Fatobene
G
,
Rocha
V
,
Kröger
N
,
Flowers
ME
.
Steroid-refractory chronic graft-versus-host disease: treatment options and patient management
.
Bone Marrow Transpl
.
2021
;
56
(
9
):
2079
-
2087
.
8.
Penack
O
,
Marchetti
M
,
Aljurf
M
, et al
.
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
.
Lancet Haematol
.
2024
;
11
(
2
):
e147
-
e159
.
9.
Sarantopoulos
S
,
Cardones
AR
,
Sullivan
KM
.
How I treat refractory chronic graft-versus-host disease
.
Blood
.
2019
;
133
(
11
):
1191
-
1200
.
10.
Sarantopoulos
S
,
Stevenson
KE
,
Kim
HT
, et al
.
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease
.
Clin Cancer Res
.
2007
;
13
(
20
):
6107
-
6114
.
11.
Mackay
F
,
Browning
JL
.
BAFF: a fundamental survival factor for B cells
.
Nat Rev Immunol
.
2002
;
2
(
7
):
465
-
475
.
12.
Shono
Y
,
Shiratori
S
,
Kosugi-Kanaya
M
, et al
.
Bone marrow graft-versus-host disease: Evaluation of its clinical impact on disrupted hematopoiesis after allogeneic hematopoietic stem cell transplantation
.
Biol Blood Marrow Transpl
.
2014
;
20
(
4
):
495
-
500
.
13.
Sarantopoulos
S
,
Stevenson
KE
,
Kim
HT
, et al
.
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease
.
Blood
.
2009
;
113
(
16
):
3865
-
3874
.
14.
Jia
W
,
Poe
JC
,
Su
H
, et al
.
BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation
.
Blood
.
2021
;
137
(
18
):
2544
-
2557
.
15.
Srinivasan
M
,
Flynn
R
,
Price
A
, et al
.
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans
.
Blood
.
2012
;
119
(
6
):
1570
-
1580
.
16.
Miklos
DB
,
Kim
HT
,
Zorn
E
, et al
.
Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors
.
Blood
.
2004
;
103
(
1
):
353
-
359
.
17.
Miklos
DB
,
Kim
HT
,
Miller
KH
, et al
.
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission
.
Blood
.
2005
;
105
(
7
):
2973
-
2978
.
18.
Umino
K
,
Morita
K
,
Ikeda
T
, et al
.
Antibody-mediated pathogenesis of chronic GVHD through DBY/HLA class II complexes and induction of a GVL effect
.
Blood
.
2023
;
142
(
11
):
1008
-
1021
.
19.
Greinix
HT
,
Kuzmina
Z
,
Weigl
R
, et al
.
CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease
.
Biol Blood Marrow Transpl
.
2015
;
21
(
2
):
250
-
258
.
20.
Kovács
KG
,
Mácsik-Valent
B
,
Matkó
J
,
Bajtay
Z
,
Erdei
A
.
Revisiting the coreceptor function of complement receptor type 2 (CR2, CD21); coengagement with the B-cell receptor inhibits the activation, proliferation, and antibody production of human B cells
.
Front Immunol
.
2021
;
12
:
620427
.
21.
Poe
JC
,
Fang
J
,
Zhang
D
, et al
.
Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD
.
JCI Insight
.
2023
;
8
(
11
):
e169732
.
22.
de Masson
A
,
Bouaziz
J-D
,
Le Buanec
H
, et al
.
CD24hi CD27+ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease
.
Blood
.
2015
;
125
(
11
):
1830
-
1839
.
23.
Gupta
NT
,
Vander Heiden
JA
,
Uduman
M
,
Gadala-Maria
D
,
Yaari
G
,
Kleinstein
SH
.
Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data
.
Bioinformatics
.
2015
;
31
(
20
):
3356
-
3358
.
24.
Vander Heiden
JA
,
Yaari
G
,
Uduman
M
, et al
.
PRESTO: a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires
.
Bioinformatics
.
2014
;
30
(
13
):
1930
-
1932
.
25.
IJspeert
H
,
van Schouwenburg
PA
,
van Zessen
D
,
Pico-Knijnenburg
I
,
Stubbs
AP
,
van der Burg
M
.
Antigen receptor galaxy: a user-friendly, web-based tool for analysis and visualization of T and B cell receptor repertoire data
.
J Immunol
.
2017
;
198
(
10
):
4156
-
4165
.
26.
Tiller
T
,
Meffre
E
,
Yurasov
S
,
Tsuiji
M
,
Nussenzweig
MC
,
Wardemann
H
.
Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning
.
J Immunol Methods
.
2008
;
329
(
1-2
):
112
-
124
.
27.
Sims
GP
,
Ettinger
R
,
Shirota
Y
,
Yarboro
CH
,
Illei
GG
,
Lipsky
PE
.
Identification and characterization of circulating human transitional B cells
.
Blood
.
2005
;
105
(
11
):
4390
-
4398
.
28.
Odendahl
M
,
Mei
H
,
Hoyer
BF
, et al
.
Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response
.
Blood
.
2005
;
105
(
4
):
1614
-
1621
.
29.
Keller
B
,
Warnatz
K
.
T-bethighCD21low B cells: the need to unify our understanding of a distinct B cell population in health and disease
.
Curr Opin Immunol
.
2023
;
82
:
102300
.
30.
Ries
S
,
Hilgenberg
E
,
Lampropoulou
V
, et al
.
B-type suppression: a role played by “regulatory B cells” or “regulatory plasma cells”?
.
Eur J Immunol
.
2014
;
44
(
5
):
1251
-
1257
.
31.
Greinix
HT
,
Pohlreich
D
,
Kouba
M
, et al
.
Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease
.
Biol Blood Marrow Transpl
.
2008
;
14
(
2
):
208
-
219
.
32.
Reincke
ME
,
Payne
KJ
,
Harder
I
, et al
.
The antigen presenting potential of CD21low B cells
.
Front Immunol
.
2020
;
11
:
535784
.
33.
Khoder
A
,
Alsuliman
A
,
Basar
R
, et al
.
Evidence for B cell exhaustion in chronic graft-versus-host disease
.
Front Immunol
.
2017
;
8
:
1937
.
34.
Grube
M
,
Holler
E
,
Weber
D
,
Holler
B
,
Herr
W
,
Wolff
D
.
Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation–results from a single-center observational study
.
Biol Blood Marrow Transpl
.
2016
;
22
(
10
):
1781
-
1791
.
35.
Wrammert
J
,
Koutsonanos
D
,
Li
GM
, et al
.
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection
.
J Exp Med
.
2011
;
208
(
1
):
181
-
193
.
36.
Jenks
SA
,
Cashman
KS
,
Zumaquero
E
, et al
.
Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus
.
Immunity
.
2018
;
49
(
4
):
725
-
739.e6
.
37.
Nakasone
H
,
Tian
L
,
Sahaf
B
, et al
.
Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans
.
Blood
.
2015
;
125
(
20
):
3193
-
3201
.
38.
Sahaf
B
,
Yang
Y
,
Arai
S
,
Herzenberg
LA
,
Herzenberg
LA
,
Miklos
DB
.
H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease
.
Proc Natl Acad Sci U S A
.
2013
;
110
(
8
):
3005
-
3010
.
39.
Kunkel
EJ
,
Butcher
EC
.
Plasma-cell homing
.
Nat Rev Immunol
.
2003
;
3
(
10
):
822
-
829
.
40.
Spencer
J
,
Sollid
LM
.
The human intestinal B-cell response
.
Mucosal Immunol
.
2016
;
9
(
5
):
1113
-
1124
.
41.
Bemark
M
,
Angeletti
D
.
Know your enemy or find your friend?–Induction of IgA at mucosal surfaces
.
Immunol Rev
.
2021
;
303
(
1
):
83
-
102
.
42.
Hong
T
,
Wang
R
,
Wang
X
, et al
.
Interplay between the intestinal microbiota and acute graft-versus-host disease: experimental evidence and clinical significance
.
Front Immunol
.
2021
;
12
:
644982
.
43.
Xu
Y
,
Zhu
Y
,
Li
X
,
Sun
B
.
Dynamic balancing of intestinal short-chain fatty acids: the crucial role of bacterial metabolism
.
Trends Food Sci Technol
.
2020
;
100
(
11
):
118
-
130
.
44.
Martín
R
,
Rios-Covian
D
,
Huillet
E
, et al
.
Faecalibacterium: a bacterial genus with promising human health applications
.
FEMS Microbiol Rev
.
2023
;
47
(
4
):
fuad039
.
45.
Holmberg
SM
,
Feeney
RH
,
Prasoodanan
PK V
, et al
.
The gut commensal Blautia maintains colonic mucus function under low-fiber consumption through secretion of short-chain fatty acids
.
Nat Commun
.
2024
;
15
(
1
):
1
-
19
.
46.
Markey
KA
,
Schluter
J
,
Gomes
ALC
, et al
.
The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD
.
Blood
.
2020
;
136
(
1
):
130
-
136
.
47.
Hockenberry
A
,
Slack
E
,
Stadtmueller
BM
.
License to clump: secretory IgA structure-function relationships across scales
.
Annu Rev Microbiol
.
2023
;
77
:
645
-
668
.
48.
Rollenske
T
,
Burkhalter
S
,
Muerner
L
, et al
.
Parallelism of intestinal secretory IgA shapes functional microbial fitness
.
Nature
.
2021
;
598
(
7882
):
657
-
661
.
49.
Paczesny
S
,
Hakim
FT
,
Pidala
J
, et al
.
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III: the 2014 Biomarker Working Group report
.
Biol Blood Marrow Transpl
.
2015
;
21
(
5
):
780
-
792
.
50.
Mei
HE
,
Frölich
D
,
Giesecke
C
, et al
.
Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab
.
Blood
.
2010
;
116
(
24
):
5181
-
5190
.
You do not currently have access to this content.
Sign in via your Institution